What the gated result supports

The dataset supports a description of 2,286 CD19-positive events as 19.0% of viable, singlet, CD45-bright lymphocyte events. It supports review of the stated controls, sequential gates, stable acquisition, and back-gating. It does not support a diagnosis, clonality assessment, normality claim, or universal antigen threshold. A fluorescence signal summary such as median fluorescence intensity is instrument- and assay-dependent unless the validated method establishes a molecule-count relationship.

No universal scatter boundary, viability percentage, event-count minimum, or specimen stability interval applies across platforms. Analyzer configuration, panel, antibody clone, fluorochrome, reagent lot, software version, template, and control criteria affect interpretation. Molecule-count signals depend on antibody binding sites: a cell with 20,000 target molecules can bind up to about 20,000 molecules of a monovalent antibody when all sites are accessible, whereas bivalent binding or inaccessible sites changes that relationship. Fluorescence therefore is not a direct universal molecule count.

Use this foundation model to read the event path and gate hierarchy, then connect it to the laboratory procedure and related immunophenotype case work. The next question is whether morphology, genetics, clinical information, and the validated assay support any clinical interpretation. Release only the result the validated method and documented review support.